Medigen Vaccine Biologics (6547) — Cash Flow Quality Index
Medigen Vaccine Biologics (6547) has a Cash Flow Quality Index of 2.69x as of September 2024. Operating cash flow of NT$4.05 Million exceeds net income of NT$1.51 Million, indicating high earnings quality where cash backs reported profits. Explore how efficiently does Medigen Vaccine Biologics generate cash to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Medigen Vaccine Biologics Cash Flow Quality Index (2021–2021)
Historical Cash Flow Quality Index for Medigen Vaccine Biologics across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 6547 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Medigen Vaccine Biologics (2021–2021)
Year-by-year earnings quality comparison for Medigen Vaccine Biologics. For live market cap and the full company financial profile, see 6547 market cap.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2021 | 0.41x | NT$579.89 Million | NT$1.41 Billion | — |